Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Jubilant Life Sciences 1Q13 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Jubilant Life Sciences 1Q13

Pharmaceutical sales rose, but Contract Services were flat.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jubilant Life Sciences
 
1Q Revenues: $227 million (+31%)
 
1Q EBITDA: $51 million (+46%)
 
Comments: Revenues from the Pharmaceutical segment were up 42% to $117 million, while Life Science Ingredients were up 18% to $110 million. CMO revenues were flat, as were revenues for Drug Discovery & Development Solutions and Healthcare. Growth in the Pharmaceutical segment was driven by generics and specialty pharma. North America revenues were $92 million (+43%), India revenues were $61 million (+15%), Europe and Japan revenues were $46 million (+38%), and Rest Of World revenues were $27 million (+12%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics